Tarsus PharmaceuticalsTARS +1.42%48 PB Ratio is 8.27 as of Jun. 25, 2026, which is 140% above its 10-year median of 3.44. GuruFocus rates TARS with a GF Score™ of 48/100 and a GF Value™ of $201.89 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, Tarsus Pharmaceuticals ranks worse than 83.29% on this metric.
The historical rank and industry rank for Tarsus Pharmaceuticals's PB Ratio or its related term are showing as below:
TARS'
s PB Ratio Range Over the Past 10 Years
Min: 1.54 Med: 3.44 Max: 10.36
Current: 8.27
During the past 8 years, Tarsus Pharmaceuticals's highest PB Ratio was 10.36. The lowest was 1.54. And the median was 3.44.
TARS's PB Ratio is ranked worse than 83.29% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs TARS: 8.27
During the past 12 months, Tarsus Pharmaceuticals's average Book Value Per Share Growth Rate was -0.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -3.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Tarsus Pharmaceuticals was 3.80% per year. The lowest was -11.00% per year. And the median was -10.10% per year.
Back to Basics: PB Ratio
Tarsus Pharmaceuticals (NAS:TARS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tarsus Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tarsus Pharmaceuticals (TARS) has a PB Ratio of 8.27 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tarsus Pharmaceuticals and its competitors. This is 140% above median its historical median of 3.44. Over the past decade, Tarsus Pharmaceuticals' PB Ratio has ranged from 1.54 to 10.36. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #1027 out of 1233 companies in the Biotechnology industry, placing it in the top 83.3%.
Is Tarsus Pharmaceuticals' PB Ratio too high?
Tarsus Pharmaceuticals' current PB Ratio of 8.27 is 140% above median its 10-year median of 3.44. Over the past 10 years, this metric has ranged from a low of 1.54 to a high of 10.36. The Biotechnology industry median PB Ratio is 2.80. Tarsus Pharmaceuticals' value of 8.27 is 195.4% above this industry median. Based on the distribution chart, Tarsus Pharmaceuticals ranks #1027 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tarsus Pharmaceuticals has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' PB Ratio compare to VERA and IDYA?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #1027 out of 1233 companies for PB Ratio. This places Tarsus Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.80. Tarsus Pharmaceuticals' value of 8.27 is 195.4% above this benchmark. Historically, Tarsus Pharmaceuticals' own PB Ratio has ranged from 1.54 to 10.36 over the past decade. While the company's 10-year median is 3.44 vs. the industry median of 2.80, Tarsus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsus Pharmaceuticals's current PB Ratio of 8.27 is 195.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current PB Ratio is 8.27, which is 140% above median its own 10-year median of 3.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $201.89, compared to a current price of $67.11 — trading 66.8% below its estimated fair value. The current PB Ratio is 8.27, which is 140% above median its 10-year median of 3.44 and 195.4% above the Biotechnology industry median of 2.80. Tarsus Pharmaceuticals' overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current PB Ratio is 8.27 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $67.11 is trading 66.8% below its estimated GF Value™ of $201.89.
GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TARS:
PB Ratio: 8.27 (140% above median its 10-year median of 3.44)
GF Value™: $201.89 vs. price of $67.11 (66.8% below fair value)
Industry Position: 195.4% above the Biotechnology median (#1027 of 1233)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
48GF Score
Get the complete analysis for TARS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
